Literature DB >> 23141496

The circulating level of FABP3 is an indirect biomarker of microRNA-1.

Francesca Varrone1, Barbara Gargano, Pierluigi Carullo, Dario Di Silvestre, Antonella De Palma, Ludovica Grasso, Carolina Di Somma, Pierluigi Mauri, Louise Benazzi, Anna Franzone, Gloria Saccani Jotti, Marie-Louise Bang, Giovanni Esposito, Annamaria Colao, Gianluigi Condorelli, Daniele Catalucci.   

Abstract

OBJECTIVES: This study sought to identify proteins from the cardiomyocyte (CM) secretome that are directly targeted by the muscle-specific microRNA-1 (miR-1), and thus reflect the pathophysiological state of the CM.
BACKGROUND: MicroRNAs play critical regulatory roles during myocardial remodeling and progression to heart failure. However, it remains unknown whether secreted microRNA-targeted proteins can be used as indicators of myocardial microRNA expression and function.
METHODS: A proteomic analysis based on multidimensional protein identification technology was performed on supernatants from cultured CMs overexpressing miR-1. Biochemical assays and an inducible cardiac-specific transgenic mouse model overexpressing miR-1 were used to demonstrate that heart-type fatty acid-binding protein-3 (FABP3) is a target of miR-1. Levels of miR-1 and FABP3 in cardiac tissue and plasma samples from mouse models as well as human patients were quantified by quantitative reverse-transcription polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. The study included wild-type mice subjected to ventricular pressure overload or fasting, as well as patients diagnosed with ventricular hypertrophy due to valvular aortic stenosis, acromegaly, or growth hormone deficiency, conditions associated with altered miR-1 expression.
RESULTS: An inverse relationship between myocardial expression of miR-1 and circulating levels of FABP3 was found both in vitro and in vivo under various pathological conditions.
CONCLUSIONS: Assessment of FABP3 plasma levels in human patients might be used for indirectly measuring cardiac miR-1 activity.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23141496     DOI: 10.1016/j.jacc.2012.08.1003

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  15 in total

Review 1.  Novel Invasive and Noninvasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases.

Authors:  Rajesh Parsanathan; Sushil K Jain
Journal:  Metab Syndr Relat Disord       Date:  2019-10-16       Impact factor: 1.894

2.  Screening for Biomarkers Associated with Left Ventricular Function During Follow-up After Acute Coronary Syndrome.

Authors:  Christina Christersson; Tomasz Baron; Frank Flachskampf; Lars Lindhagen; Bertil Lindahl; Agneta Siegbahn
Journal:  J Cardiovasc Transl Res       Date:  2022-06-21       Impact factor: 4.132

Review 3.  MicroRNAs in heart failure: Non-coding regulators of metabolic function.

Authors:  Xiaokan Zhang; P Christian Schulze
Journal:  Biochim Biophys Acta       Date:  2016-08-18

Review 4.  Heart failure: advanced development in genetics and epigenetics.

Authors:  Jian Yang; Wei-Wei Xu; Shen-Jiang Hu
Journal:  Biomed Res Int       Date:  2015-04-09       Impact factor: 3.411

Review 5.  Review in Translational Cardiology: MicroRNAs and Myocardial Fibrosis in Aortic Valve Stenosis, a Deep Insight on Left Ventricular Remodeling.

Authors:  Fabiani Iacopo; Conte Lorenzo; Enrico Calogero; Passiatore Matteo; Pugliese Nicola Riccardo; Santini Veronica; Barletta Valentina; Liga Riccardo; Scatena Cristian; Mazzanti Chiara Maria; Di Bello Vitantonio
Journal:  J Cardiovasc Echogr       Date:  2016 Oct-Dec

Review 6.  MicroRNA as a Therapeutic Target in Cardiac Remodeling.

Authors:  Chao Chen; Murugavel Ponnusamy; Cuiyun Liu; Jinning Gao; Kun Wang; Peifeng Li
Journal:  Biomed Res Int       Date:  2017-09-28       Impact factor: 3.411

Review 7.  Non-coding RNAs in cardiac hypertrophy.

Authors:  Lara Ottaviani; Paula A da Costa Martins
Journal:  J Physiol       Date:  2017-04-23       Impact factor: 5.182

Review 8.  Overview of MicroRNAs in Cardiac Hypertrophy, Fibrosis, and Apoptosis.

Authors:  Juan Wang; Oi Wah Liew; Arthur Mark Richards; Yei-Tsung Chen
Journal:  Int J Mol Sci       Date:  2016-05-18       Impact factor: 5.923

Review 9.  MicroRNAs in Valvular Heart Diseases: Potential Role as Markers and Actors of Valvular and Cardiac Remodeling.

Authors:  Cécile Oury; Laurence Servais; Nassim Bouznad; Alexandre Hego; Alain Nchimi; Patrizio Lancellotti
Journal:  Int J Mol Sci       Date:  2016-07-13       Impact factor: 5.923

Review 10.  Epigenome alterations in aortic valve stenosis and its related left ventricular hypertrophy.

Authors:  Igor Gošev; Martina Zeljko; Željko Đurić; Ivana Nikolić; Milorad Gošev; Sanja Ivčević; Dino Bešić; Zoran Legčević; Frane Paić
Journal:  Clin Epigenetics       Date:  2017-10-03       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.